High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin's lymphoma.
Glasmacher
Axel
A
Department of Internal Medicine I, University of Bonn, Germany. glasmacher@uni-bonn.de <glasmacher@uni-bonn.de>